DaVita has notified Gambro that it is terminating the Alliance and Product Supply Agreement

May 30, 2006

DaVita has notified Gambro that it is terminating the Alliance and Product Supply Agreement dated as of October 5, 2005, among DaVita, Gambro AB and Gambro Renal Products, Inc.. The agreement was signed as a part of the agreement to divest Gambro’s dialysis clinics business in the U.S., Gambro Healthcare U.S., to DaVita Inc.

The reason given by DaVita for its notice of termination is primarily related to the inability of Gambro Renal Products to provide DaVita with monitors due to the Import Alert related to the Warning Letter issued by the FDA in January 2006. Gambro does not believe the company’s performance to date has in any way resulted in a breach in the Agreement. The Supply Agreement provides for a cure period of ninety days following notice, accordingly Gambro has a time period to respond to DaVita’s raised issues.

“We view our relationship as a partnership and it is important to us that our arrangements will be mutually beneficial. Gambro is committed to being flexible where possible to address the concerns voiced by DaVita” says Gambro President and CEO Sören Mellstig.

Gambro is fully committed to resolve this situation, using the existing mechanisms under the Agreement. “Our goal has been and will continue to be to insure that DaVita’s needs are met today and in the future.” says Jon Risfelt, President Gambro Renal Products.

The supply agreement is important for the development of Gambro Renal Products and DaVita is a key customer. It’s today too early to give any indication on possible financial impact.

For further information please contact: Paula Treutiger, Vice President, Corporate Communications, tel. +46-8-613 65 99, +46-73-366 65 99 Sophie Monsén, Manager, Investor Relations, Corporate Finance, tel. +46-8-613 65 02, +46-73-366 65 02 Kevin Smith, President Gambro Inc., Investor Relations US, tel. +1-303 231 4750

Gambro is a global medical technology company with related services and has leading positions in renal care - services and products - and blood component technology. Gambro Renal Products develops and supplies hemodialysis, peritoneal dialysis, and acute renal and liver dialysis products, therapies and services. Gambro Healthcare is a provider of end-stage renal disease treatment and patient care. Gambro BCT develops and provides blood collection, apheresis and cell therapy products and services.

Contact Information

Paula Treutiger

Vice President, Corporate Communications

Gambro Inc.

Contact via E-mail